Hernia Mesh Litigation (Multiple Manufacturers & MDLs)

Surgical mesh has been widely used to repair hernias since the 1990s, with over one million hernia repairs performed annually in the United States. While tension-free mesh repair became the standard of care — reducing hernia recurrence rates compared to traditional suture repair — certain mesh products have been linked to devastating complications that can be worse than the original hernia.

Complications include mesh shrinkage and contraction (some products shrink by up to 50% after implantation), adhesion of the mesh to bowel and other internal organs, chronic debilitating pain, infection that may require complete mesh removal, mesh migration from the original implant location, fistula formation (abnormal connections between organs), and bowel obstruction. Many patients require one or more complex revision surgeries — procedures that carry their own significant risks and often cannot fully resolve the complications.

Multiple manufacturers face litigation across several MDLs. C.R. Bard (now part of Becton Dickinson) faces the largest MDL (No. 2846, S.D. Ohio) with approximately 24,000 pending cases over its Ventralex, Kugel, and other product lines. Atrium Medical faces claims over its C-QUR mesh, which uses a novel omega-3 fish oil coating. Ethicon (J&J) faced claims over its Physiomesh, which was voluntarily withdrawn from the market in 2016 after post-market data showed higher-than-expected rates of complication.

The FDA issued safety communications in 2011 and 2016 noting thousands of adverse event reports related to hernia mesh. The agency reclassified surgical mesh for transvaginal repair as high-risk (Class III) in 2016 — a related but separate litigation track.

Hernia mesh complications arise from the body's foreign body response to synthetic materials. Polypropylene — the most common mesh material — triggers a chronic inflammatory reaction that can lead to fibrosis (scar tissue formation), adhesion to adjacent organs, and mesh contraction. Heavyweight, large-pore polypropylene meshes have been associated with higher complication rates than lighter-weight alternatives.

Atrium Medical's C-QUR mesh used an omega-3 fatty acid (fish oil) coating intended to reduce adhesions. However, plaintiffs allege the coating was inadequately tested, may degrade unpredictably, and may itself trigger inflammatory reactions in some patients.

Ethicon's Physiomesh was a composite mesh voluntarily withdrawn from the global market in May 2016 after an analysis of two European hernia registries showed higher-than-expected rates of hernia recurrence and reoperation compared to competitor products.

The FDA received over 100,000 adverse event reports related to surgical mesh (including both hernia and pelvic mesh) between 2005 and 2019, making it one of the most-reported medical device categories. FDA safety communications in 2011 and 2016 acknowledged the complication risks.

Eligible individuals may include patients who received hernia mesh implants and subsequently experienced complications such as chronic pain, infection, mesh migration, bowel obstruction, organ adhesion, mesh contraction, fistula formation, or required revision surgery. Claims exist for products from multiple manufacturers including C.R. Bard, Atrium Medical, Ethicon (J&J), and Covidien (Medtronic).

This eligibility information is general and informational only. Consult a licensed attorney.

The C.R. Bard hernia mesh MDL (No. 2846) is the largest, with approximately 24,000 pending cases in the Southern District of Ohio before Judge Edmund A. Sargus Jr. Bellwether trials are expected in 2026.

The Atrium C-QUR mesh MDL is in the District of New Hampshire. The Covidien MDL is in the District of Massachusetts. The Ethicon Physiomesh litigation has largely been resolved through settlements.

Thousands of individual cases have been resolved through settlement programs established by various manufacturers. However, tens of thousands of cases remain active.

C.R. Bard (Becton Dickinson) has argued that its hernia mesh products were FDA-cleared, properly designed, and safe for their intended use. The company contends that hernia mesh complications are a known risk of any surgical mesh procedure and that its products performed comparably to competitors.

Ethicon argued that its Physiomesh was voluntarily withdrawn as a precautionary measure based on registry data, not because the product was defective. All defendants have emphasized that mesh repair remains the standard of care for most hernias and has significantly lower recurrence rates than suture repair.

Defendants generally argue that the complications experienced by individual plaintiffs resulted from surgical technique, patient anatomy, and other factors rather than product defects.

Multiple manufacturers have settled thousands of hernia mesh claims, though individual settlement amounts are generally confidential. C.R. Bard has settled significant numbers of cases. Atrium Medical reached settlements for its C-QUR product line. Ethicon resolved Physiomesh claims.

Individual trial verdicts have ranged from several million to over $50 million. Total manufacturer exposure across all hernia mesh MDLs is estimated in the billions of dollars.

Past settlement amounts are not a guarantee of future results. Individual claim values vary significantly.